The Tenosynovial Giant Cell Tumors Market size in the 7MM will increase at a CAGR of 8% due to increasing awareness of the disease and the launch of emerging therapies | Major Companies- Deciphera Pharmaceuticals, SynOx Therapeutics (Celleron Therapeutics

The Tenosynovial Giant Cell Tumor market report provides current treatment practices, Tenosynovial Giant Cell Tumor emerging drugs, Tenosynovial Giant Cell Tumor market share of individual therapies, and current and forecasted epidemiology in 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032. Tenosynovial Giant Cell Tumor Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Tenosynovial Giant Cell Tumor clinical trials profiles, key cross-competition, launch date along with product development activities.

The Tenosynovial Giant Cell Tumor Market research report conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The Tenosynovial Giant Cell Tumor market driving factors, market overview, industry volume, and market share are also highlighted in this Tenosynovial Giant Cell Tumor Market report analysis.

Key Takeaways from the Tenosynovial Giant Cell Tumor Market Report

• Most Tenosynovial Giant Cell Tumor patients have a localized growth pattern, with approximately 12,610 incident cases in the United States.
• In 2022, the market size of Tenosynovial Giant Cell Tumor was the highest in the US among the 7MM, accounting for approximately USD 150 million, which is further expected to increase by 2032.
• The leading Tenosynovial Giant Cell Tumor Companies include Deciphera Pharmaceuticals, SynOx Therapeutics (Celleron Therapeutics), Daiichi Sankyo Inc. and others
• Promising Tenosynovial Giant Cell Tumor Pipeline Therapies include Pexidartinib, TURALIO (pexidartinib), Vimseltinib (DCC-3014), and others

Explore more information about the Latest Drugs Launch, New Breakthroughs of Drugs or Therapies Approaches, Treatment Practices, and Forecasted Epidemiology @ Tenosynovial Giant Cell Tumor Market Size- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Tenosynovial Giant Cell Tumor Overview
Tenosynovial Giant Cell Tumor is an abnormal growth of tissue derived from the synovium that causes activation of immune cells, specifically macrophages, leading to mass formation. These tumors are often classified by their growth pattern (localized or diffused) and location (intra-or extra-articular). Recurrences are quite common in Tenosynovial Giant Cell Tumors, a major concern for decisions regarding treatment choice.

Tenosynovial Giant Cell Tumor Epidemiology Segmentation
• Tenosynovial Giant Cell Tumors Incident Cases
• Tenosynovial Giant Cell Tumors Growth-Pattern Specific Incident Cases
• Tenosynovial Giant Cell Tumors Gender-specific Incident Cases of localized
• Total Tenosynovial Giant Cell Tumors Treated Cases

Download the report to understand which factors are driving Tenosynovial Giant Cell Tumors epidemiology trends @ Tenosynovial Giant Cell Tumors Epidemiological Insights- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Tenosynovial Giant Cell Tumors Marketed Drugs

• TURALIO (pexidartinib): Daiichi Sankyo
TURALIO (pexidartinib) is an orally administered small molecule tyrosine kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation. The US FDA approves it for treating adult patients with symptomatic tenosynovial giant cell tumors associated with severe morbidity or functional limitations which are not amenable to improvement with surgery.

TURALIO received approval for the treatment of tenosynovial giant cell tumor patients in August 2019 in the United States. A new dosing regimen of TURALIO was introduced in February 2023, where the 200 mg capsule was discontinued and replaced by a 125 mg capsule. The new recommended dose, which the FDA approved in October 2022, is 125 mg capsules taken twice daily with a low-fat meal, instead of the former 200 mg capsules taken twice daily on an empty stomach. This was done to reduce the toxic effects of the drug.

TURALIO is expected to face heavy competition from therapies such as Deciphera Pharmaceuticals' vimseltinib and SynOx Therapeutics' emactuzumab, which have demonstrated significantly better safety and efficacy profiles than TURALIO in clinical trials.

Tenosynovial Giant Cell Tumors Emerging Drugs

• Vimseltinib (DCC-3014): Deciphera Pharmaceuticals
Vimseltinib (DCC-3014), which is being developed by Deciphera Pharmaceuticals, is an orally administered, potent, and highly-selective switch-control kinase inhibitor of the colony-stimulating factor 1 receptor (CSF1R) with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. The drug could be the best-in-class treatment for tenosynovial giant cell tumor patients. The Phase I/II study demonstrated promising preliminary results, encouraging antitumor activity with clinical benefits and manageable adverse events. These results supported its continued evaluation in a Phase III MOTION study, which, if successful, will lead to the FDA approval of the drug before 2026. Key opinion Leaders (KOLs) are convinced with the tolerability and antitumor activity of vimseltinib in clinical trials and have shown a preference toward vimseltinib over imatinib and pexidartinib, for the treatment of tenosynovial giant cell tumors.

Tenosynovial Giant Cell Tumors Market Outlook

Tenosynovial Giant Cell Tumor treatment in the US has entered a new era, with the dynamics expected to change. Surgery is the primary therapeutic option for Tenosynovial Giant Cell Tumors, but it is frequently accompanied by recurrences and hampering the patient's functional status. When the tumor is removed as a whole, the likelihood of the recurrence of the tumor is reduced; however, complete removal of the tumor sometimes requires the mandatory undesirable removal of the functional structures of the patient. But if the tumor is removed partially to maintain a patient's functional status, recurrences are much more likely to appear.

Tenosynovial Giant Cell Tumors Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers' concerns about budget impact. The high cost of rare disease drugs usually has a limited impact on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs etc.

Learn more about the FDA-approved drugs for Tenosynovial Giant Cell Tumors @ Tenosynovial Giant Cell Tumors Market Drivers and Barriers- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Tenosynovial Giant Cell Tumors Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Tenosynovial Giant Cell Tumor Companies- Deciphera Pharmaceuticals, SynOx Therapeutics (Celleron Therapeutics), Daiichi Sankyo Inc. and others
• Tenosynovial Giant Cell Tumor Pipeline Therapies include Pexidartinib, TURALIO (pexidartinib), Vimseltinib (DCC-3014), and others.
• Tenosynovial Giant Cell Tumor Market Dynamics: Tenosynovial Giant Cell Tumor Market Drivers and Barriers

Discover more about Tenosynovial Giant Cell Tumor Drugs in development @ Tenosynovial Giant Cell Tumor Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. TGCT Market Overview at a Glance
4. Executive Summary of Tenosynovial Giant Cell Tumor (TGCT)
5. Epidemiology and Market Methodology
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Patient Journey
9. Key Endpoints in Tenosynovial Giant Cell Tumor Clinical Trials (TGCT)
10. Emerging Therapies
11. Tenosynovial Giant Cell Tumor: The 7MM Analysis
12. Market Access and Reimbursement
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

Got Queries? Reach out for more information about the Patient Population, Treatment Algorithm, Unmet Needs, and Emerging Drugs of the report @ Tenosynovial Giant Cell Tumors Market Dynamics- https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

This release was published on openPR.